124
Participants
Start Date
August 19, 2014
Primary Completion Date
June 7, 2016
Study Completion Date
August 31, 2019
Ipatasertib
Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
Paclitaxel
Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
Placebo
Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
Chang Gung Medical Foundation - Linkou; Dept of Surgery, Taoyuan District
Chi Mei Medical Center, Yong kang; Endocrinology, Tainan City
Sint Augustinus Wilrijk, Wilrijk
National Taiwan University Hospital, Taipei
National Cancer Center, Goyang-si
Seoul National University Bundang Hospital, Seongnam-si
Centre Francois Baclesse, Caen
Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, Milan
Clinique Armoricaine de Radiol, Saint-Brieuc
Complejo Hospitalario de Jaen, Jaén
West Virginia University Hospitals Inc, Morgantown
MD Anderson Cancer Center, Madrid
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Farmacia, Madrid
Carolinas Healthcare System, Charlotte
Memorial Healthcare System, Hollywood
Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux
Holycross Medical Group, Fort Lauderdale
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
Istituto Oncologico Veneto IRCCS Farmacia Ospedaliera, Padua
The WEST CLINIC, P.C., Memphis
China Medical University Hospital, North Dist.
Hospital Virgen del Rocio, Seville
Rush University Medical Center, Chicago
Hopital Saint Louis; Oncologie Medicale, Paris
MD Anderson Cancer Center, Houston
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Northern Utah Associates, Ogden
Comprehensive Cancer Centers of Nevada, Henderson
Cedars Sinai Medical Center, Los Angeles
UCLA Medical Center, Santa Monica
St Jude Heritage Medical Group, Fullerton
Northwest Medical Specialties, Lakewood
National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore
National Cancer Centre, Singapore
Cancer Care Assoc Med Group, Los Angeles
Cancer Center of Kansas, Wichita
Massachusetts General Hospital Cancer Center, Boston
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Korea University Guro Hospital, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona
Lead Sponsor
Genentech, Inc.
INDUSTRY